Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
SeekIn Receives CE Mark Approval for OncoSeek® Multi-Cancer Detection Test
SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE […]
Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer
Compugen Ltd. ( Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced […]
Zejula (Niraparib) Shows Durable and Sustained Long-term Progression-free Survival Benefit in the Prima Study of First-line Platinum-responsive Advanced Ovarian Cancer
GSK plc (LSE/NYSE: GSK) today announced long-term data from the phase III PRIMA (ENGOT-OV26/GOG-3012) study […]
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-Tumor Activity in Two Advanced Solid Tumors
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific […]
Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer
Privo Technologies, Inc. (“Privo”, “the Company”) announced today that it has been awarded a $2M Direct-to-Phase II SBIR […]
NeoImmuneTech's NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab
NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus […]
Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations
Deka Biosciences (“Deka”), a biotech company focused on the development of novel cytokine therapies to […]
Freenome Launches Its First Study for the Detection of Multiple Cancers That Pairs Multiomics With Real-World Data
Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the […]
Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments
Verseon is pleased to announce that the European Patent Office has granted intellectual property protection […]
Elephas Announces $41.5 Million in Series B Funding
Elephas Biosciences Corporation (Elephas), a private company, announced today that it has raised $41.5 million in Series […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more